Piotr Siciński

Active 1988–2024

Also published as
Piotr Sicinski
78
Papers
22,168
Citations
69
h-index
78
i10-index

Citations

Citations per year for Piotr Siciński1974: 2 citations1981: 1 citations1987: 1 citations1989: 9 citations1990: 10 citations1991: 20 citations1992: 14 citations1993: 21 citations1994: 12 citations1995: 13 citations1996: 37 citations1997: 44 citations1998: 58 citations1999: 100 citations2000: 123 citations2001: 142 citations2002: 161 citations2003: 146 citations2004: 229 citations2005: 208 citations2006: 229 citations2007: 147 citations2008: 150 citations2009: 197 citations2010: 137 citations2011: 112 citations2012: 170 citations2013: 155 citations2014: 139 citations2015: 165 citations2016: 174 citations2017: 197 citations2018: 236 citations2019: 729 citations2020: 924 citations2021: 848 citations2022: 796 citations2023: 601 citations2024: 909 citations2025: 456 citations2026: 14 citations1975–1980: no citations, so these years are not shown1982–1986: no citations, so these years are not shown1988: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,990 citing papers, 30.7% of this breakdownChina: 1,859 citing papers, 19.1% of this breakdownUnited Kingdom: 573 citing papers, 5.9% of this breakdownGermany: 381 citing papers, 3.9% of this breakdownFrance: 304 citing papers, 3.1% of this breakdownCanada: 286 citing papers, 2.9% of this breakdownItaly: 263 citing papers, 2.7% of this breakdownJapan: 261 citing papers, 2.7% of this breakdownSpain: 245 citing papers, 2.5% of this breakdownAustralia: 242 citing papers, 2.5% of this breakdownNetherlands: 175 citing papers, 1.8% of this breakdownIndia: 166 citing papers, 1.7% of this breakdown
0%30.7%Other 20.5%

Fields

  • Biochemistry, Genetics and Molecular Biology47%
  • Medicine43.1%
  • Immunology and Microbiology3.7%
  • Neuroscience2.3%
  • Agricultural and Biological Sciences1%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other2.4%

Topics

  • Cancer-related Molecular Pathways7.3%
  • Advanced Breast Cancer Therapies3.5%
  • Epigenetics and DNA Methylation3.2%
  • Ubiquitin and proteasome pathways2.9%
  • Microtubule and mitosis dynamics2.8%
  • Cancer Immunotherapy and Biomarkers2%
  • Other78.3%

Coauthors

All papers

Open in search
  1. Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

    Authors: , , , , , , , , , , , , , , , , , - Nature 2017 cited by 1,049

  2. Cell cycle proteins as promising targets in cancer therapy

    Authors: , - Nature reviews. Cancer 2017 cited by 1,904

  3. CDK4 and CDK6 kinases: From basic science to cancer therapy

    Authors: , , - Science 2022 cited by 467

  4. Targeting cell-cycle machinery in cancer

    Authors: , , , - Cancer Cell 2021 cited by 568

  5. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cell Biology 2020 cited by 393

  6. The cell cycle in stem cell proliferation, pluripotency and differentiation

    Authors: , , , - Nature Cell Biology 2019 cited by 431

  7. Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian C. Dibble, John M. Asara, Gyongy Szabo, Piotr Siciński, Ji Miao, Yu-Ru Lee, Lifeng Pan, Reuben J. Shaw, Junying Yuan, Wenyi Wei - Science 2023 cited by 118

  8. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2018 cited by 254

  9. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases

    Authors: , , - Nature Reviews Molecular Cell Biology 2016 cited by 538

  10. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

    Authors: , , , , , , , , , , , , , , , , , - Cancer Cell 2016 cited by 488

  11. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation

    Authors: , , , , , - eLife 2014 cited by 464

  12. JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Henry W. Long, Beth Overmoyer, Kornélia Polyák - Cancer Research 2022 cited by 101

  13. PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity

    Authors: , , , , , , , - Nature Communications 2023 cited by 75

  14. Cyclin E in normal physiology and disease states

    Authors: , , , - Trends in Cell Biology 2021 cited by 162

  15. A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells

    Authors: , , , , , , , , , , - Cancer Cell 2011 cited by 550

  16. CDC7-independent G1/S transition revealed by targeted protein degradation

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature 2022 cited by 94

  17. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2014 cited by 367

  18. The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival

    Authors: , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 354

  19. The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation

    Authors: , , , , , - Science 1989 cited by 1,225

  20. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Communications 2020 cited by 95

  21. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27

    Authors: , , , , , , , , , , , , - Scientific Reports 2019 cited by 74

  22. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer

    Authors: , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 50

  23. Cdk1 Controls Global Epigenetic Landscape in Embryonic Stem Cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Cell 2020 cited by 123

  24. Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Science Advances 2020 cited by 105